Jefferies Says No Changes to Ests on Amgen (AMGN) Amid Parsabiv CRL; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Stock futures lower as countdown to Yellen speech begins
August 25, 2016 7:25 AM EDTBy Yashaswini Swamynathan
(Reuters) - U.S. stock index futures were slightly lower on Thursday, with investors on the sidelines as they wait for more clarity from the Federal Reserve its path to raise interest rates.
* Investors have been waiting for Fed Chair Janet Yellen's address at an annual meeting of global central bankers in Jackson Hole, Wyoming, for signals on the timing of the next rate hike.
* While traders have priced in a marginal chance of a hike when the Fed meets in September, Yellen's... More
Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird
August 25, 2016 7:09 AM EDTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the Parsabiv FDA rejection. Amgen's Parsabiv, a calcimimetic under review by the FDA for secondary hyperthyroidism, received a complete response letter. Amgen has spoken positively about the program... More
Amgen (AMGN) Receives CRL from FDA on Parsabiv NDA
August 24, 2016 6:06 PM EDTAmgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney... More
